Brain tumours are the leading cause of cancer-related death in children and young adults. A major challenge to improving this outcome, is developing effective treatments that can cross the protective ‘blood brain barrier’ to directly target tumours in the brain.
Now, a new international consortium has been launched to bring together world-leading experts to take on this challenge, by exploring the use of novel drug delivery systems to physically bypass the blood brain barrier.
The Children’s Brain Tumour Drug Delivery Consortium, led by Professor David Walker at The University of Nottingham, is a two-year initiative funded with a £194,000 grant from the national charity Children with Cancer UK.
David Walker, Professor of Paediatric Oncology and Co-Director of the University’s Children’s Brain Tumour Research Centre, said: “This consortium was born from a strong need for sharing knowledge and expertise within the area of childhood brain tumour drug delivery, in order to make significant headway in this challenging area.
“This will be the first time that there has ever been global coordination of a paediatric brain tumour drug delivery consortium, offering unrivalled opportunities for open dialogue and sharing of resources, which in turn will accelerate translational research in this area.”
The Consortium will organise and host discussions of an international, multi-disciplinary network of clinicians and researchers committed to developing drug delivery systems to enable effective treatment of children with brain tumours.
Through raising awareness and sharing expertise with a range of stakeholders, it will be uniquely placed to strengthen collaborative developments in the field of drug delivery.
The consortium’s network of experts, initially from eight institutions across North America and Europe, will promote a more joined up approach to assessing whether innovative new drug delivery methods, and those that have been successfully used to treat other types of cancer, could become a new avenue for tackling childhood brain tumours.
This includes Intra-CSF therapy, an intrathecal drug delivery system that injects chemotherapy drugs directly into the spinal fluid or brain, and interstitial therapy, for example the implantation of drug-loaded wafers into the cavity that is exposed during surgery to remove a tumour.
The consortium will also highlight the importance of the field to funders, industry and regulators, while working closely with patient and carer charities and not-for-profits to ensure the priorities and perspectives of patients are strongly represented.
Mark Hooley, Head of Communications at Children with Cancer UK said:
“We are pleased to be supporting the early first phase of this truly international Consortium.
“It is a fantastic continuation from our Drug Delivery Workshop held earlier this year. The Consortium ensures that this important problem remains at the forefront of scientific and clinical priorities. Through international collaboration we hope they can accelerate the progress in developing better treatments for children with brain tumours.
“Thanks to our supporters we can continue to fund vital initiatives like this and ultimately lead to safer and more effective treatment for children with brain tumours.”
The Children’s Brain Tumour Research Centre at The University of Nottingham was established in 1997 in a bid to drive forward new developments in paediatric brain tumour research. Its world-leading academics have played a leading role in calling for an increase in funding for brain tumours, successfully lobbied for a reduction in red tape hampering clinical trials in brain tumours in Europe and initiated the Brain Pathways project, which developed the clinical referral guidance for children with symptoms and signs of brain tumour, now endorsed by NHS Evidence and the focus of an awareness campaign, called HeadSmart Be Brain Tumour Aware.
The consortium involves academics and specialists from the Children’s Brain Tumour Research Centre, the University of Strathclyde, Bristol Royal Hospital for Children, Newcastle University, UCL Institute of Child Health, Fast Track Pharma Ltd and Macrophage Pharma Ltd in the UK; Johns Hopkins University and the National Cancer Institute in the US, and VU University Medical Center in the Netherlands.
Learn more about the work of the Children’s Brain Tumour Research Centre and its research into drug delivery via a series of videos on its website.
— Ends —
Our academics can now be interviewed for broadcast via our Media Hub, which offers a Globelynx fixed camera and ISDN line facilities at University Park campus. For further information please contact a member of the Communications team on +44 (0)115 951 5798, email email@example.com or see the Globelynx website for how to register for this service.
For up to the minute media alerts, follow us on Twitter
Notes to editors: The University of Nottingham has 43,000 students and is ‘the nearest Britain has to a truly global university, with a “distinct” approach to internationalisation, which rests on those full-scale campuses in China and Malaysia, as well as a large presence in its home city.’ (Times Good University Guide 2016). It is also one of the most popular universities in the UK among graduate employers and was named University of the Year for Graduate Employment in the 2017 The Times and The Sunday Times Good University Guide. It is ranked in the world’s top 75 by the QS World University Rankings 2015/16, and 8th in the UK for research power according to the Research Excellence Framework 2014. It has been voted the world’s greenest campus for four years running, according to Greenmetrics Ranking of World Universities.
Impact: The Nottingham Campaign, its biggest-ever fundraising campaign, is delivering the University’s vision to change lives, tackle global issues and shape the future. More news…